查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654295

破伤风类毒素疫苗市场规模、份额、趋势分析报告：按疫苗、疾病、最终用途、地区、细分预测，2025-2030 年

Tetanus Toxoid Vaccine Market Size, Share & Trends Analysis Report By Vaccine (Diphtheria, Tetanus, And Pertussis (DTaP)), By Disease (Tetanus, Diphtheria), By End Use (Hospital, Specialty Clinics), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 153 Pages | 商品交期: 2-10个工作天内

价格

破伤风类毒素疫苗市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球破伤风类毒素疫苗市场预计到2030年将达到80.9亿美元，2025年至2030年期间的复合年增长率为5.67%。

由于人们对免疫计划的关注度不断提高以及对疫苗可预防疾病的认识不断提高，破伤风类毒素疫苗行业正在经历显着增长。破伤风是严重细菌感染疾病，仍然是全球健康问题，特别是在疫苗接种覆盖率较低的地区。疫苗接种的普及和医疗保健基础设施的发展是推动市场扩张的主要因素。

推动市场成长的一个主要因素是能够提供针对多种疾病的广谱保护的联合疫苗。白喉-破伤风-百日咳 (DTaP) 疫苗在小儿科免疫接种计画中广泛使用，可确保早期预防这些严重感染疾病。同样，白喉破伤风 (DT) 疫苗对于无法接种百日咳疫苗的人来说是必不可少的，并支持替代疫苗接种选择。此外，破伤风-白喉-百日咳（Tdap）疫苗在青少年和成年人的加强免疫中发挥重要作用，可以增强长期免疫力，减少疾病传播。

根据目标疾病对疫苗进行分类，进一步增强了该市场。儘管以破伤风为重点的疫苗仍然是免疫策略的核心，但结合白喉预防将提高整体有效性。加入针对特定病患小组定制的其他疫苗配方将允许采取更全面的疫苗接种方法，扩大不同人群的接种机会。

分销管道在疫苗推广中发挥着至关重要的作用。作为主要的疫苗接种中心，医院可以方便地提供破伤风类毒素疫苗，特别是在紧急伤口处理情况下。专科诊所透过提供常规疫苗接种做出了重大贡献，特别是针对孕妇和旅行者等高风险族群。此外，社区健康中心和药局等其他医疗服务提供者也正在扩大其在疫苗接种服务中的作用，提高其市场渗透率。

随着疫苗配方的不断进步和政府提高疫苗接种覆盖率的倡议不断增多，预计未来几年市场将实现稳步增长。

破伤风类毒素疫苗市场报告重点

  • 在 2024 年破伤风类毒素疫苗产业中，白喉-破伤风-百日咳 (DTaP) 占疫苗领域的最大份额。这项优势归功于 DTaP 在常规免疫计划中的广泛应用，特别是在儿童和加强疫苗接种计划中，可为多种细菌感染提供全面的保护。
  • 根据疾病，破伤风将继续成为 2024 年市场成长的主要贡献者。破伤风相关併发症的发生率很高，尤其是在未接种疫苗的人群以及新生儿和创伤患者等高风险人群中，这增加了对有效疫苗接种策略的需求，使得破伤风类毒素疫苗接种变得越来越重要。
  • 在终端使用领域，医院将在 2024 年占据市场主导地位。医院在疫苗接种计划、紧急预防和破伤风暴露后管理中发挥关键作用，确保及时接种疫苗，特别是在治疗损伤和伤口方面。训练有素的医疗专业人员的存在进一步提高了医院疫苗接种的效率。
  • 由于先进的医疗基础设施、完善的疫苗接种计划以及人们对疫苗可预防疾病的认识不断提高，北美在 2024 年引领了市场。政府推出的优惠政策和倡议，推动常规和补贴免疫，进一步增强了该地区的市场优势。

目录

第一章调查方法与范围

第 2 章执行摘要

3. 破伤风类毒素疫苗市场变因、趋势与范围

  • 母市场展望
  • 补贴市场前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 破伤风类毒素疫苗分析工具
    • 波特的分析
    • PESTEL 分析

第 4 章破伤风类毒素疫苗市场：疫苗估计与趋势分析

  • 破伤风类毒素疫苗市场：疫苗区隔仪表板
  • 破伤风类毒素疫苗市场：疫苗变异分析，2024 年及 2030 年
  • 白喉、破伤风和百日咳 (DTaP)
  • 白喉和破伤风 (DT)
  • 破伤风-白喉-百日咳 (Tdap)

第 5 章破伤风类毒素疫苗市场：疾病评估与趋势分析

  • 破伤风类毒素疫苗市场：疾病区隔仪表板
  • 破伤风类毒素疫苗市场：疾病变异分析，2024 年及 2030 年
  • 破伤风
  • 白喉
  • 其他的

6. 破伤风类毒素疫苗市场：最终用途估计与趋势分析

  • 破伤风类毒素疫苗市场：最终用途细分仪表板
  • 破伤风类毒素疫苗市场：2024 年和 2030 年最终用途变化分析
  • 医院
  • 专科门诊
  • 其他的

第 7 章破伤风类毒素疫苗市场：区域估计与趋势分析

  • 2024 年及 2030 年破伤风类毒素疫苗各地区市场占有率
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 挪威
    • 瑞典
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特
    • 南非

第八章 竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 公司热图分析
  • 公司简介
    • Pfizer, Inc.
    • GSK plc.
    • Sanofi
    • Merck &Co., Inc.
    • Grifols, SA
    • Emergent BioSolutions Inc.
    • Virbac
    • Zoetis Services LLC
    • Ceva.
    • Abbott
Product Code: GVR-4-68040-502-4

Tetanus Toxoid Vaccine Market Growth & Trends:

The global tetanus toxoid vaccine market size is anticipated to reach USD 8.09 billion by 2030 and is expected to expand at a CAGR of 5.67% from 2025 to 2030, according to a new report by Grand View Research, Inc. The tetanus toxoid vaccine industry is witnessing significant growth due to the increasing focus on immunization programs and rising awareness about vaccine-preventable diseases. Tetanus, a severe bacterial infection affecting the nervous system, remains a global health concern, particularly in regions with low vaccination coverage. The expanding adoption of vaccination drives and improved healthcare infrastructure are key factors propelling market expansion.

A major contributor to market growth is the availability of combination vaccines, which provide broader protection against multiple diseases. The Diphtheria, Tetanus, and Pertussis (DTaP) vaccine is widely administered in pediatric immunization schedules, ensuring early protection against these serious infections. Similarly, the Diphtheria and Tetanus (DT) vaccine is essential for individuals who cannot receive the pertussis component, supporting alternative immunization options. Additionally, the Tetanus, Diphtheria, and Pertussis (Tdap) vaccine plays a crucial role in booster doses for adolescents and adults, reinforcing long-term immunity and reducing disease transmission.

The market is further strengthened by the classification of vaccines based on target diseases. While Tetanus-focused vaccines remain central to immunization strategies, the integration of Diphtheria protection enhances overall effectiveness. The inclusion of other vaccine formulations tailored for specific patient groups contributes to a more comprehensive immunization approach, expanding accessibility across diverse populations.

Distribution channels play a pivotal role in ensuring widespread vaccine availability. Hospitals serve as primary immunization centers, offering immediate access to tetanus toxoid vaccines, especially in emergency wound management cases. Specialty clinics contribute significantly by providing routine vaccinations, particularly for high-risk groups such as pregnant women and travelers. Additionally, other healthcare providers, including community health centers and pharmacies, are expanding their role in vaccination services, enhancing market penetration.

With continuous advancements in vaccine formulations and increasing governmental efforts to improve immunization rates, the market is poised for steady growth in the coming years.

Tetanus Toxoid Vaccine Market Report Highlights:

  • The vaccine segment of Diphtheria, Tetanus, and Pertussis (DTaP) held the largest share of the tetanus toxoid vaccine industry in 2024. This dominance can be attributed to the widespread adoption of DTaP in routine immunization programs, offering comprehensive protection against multiple bacterial infections, particularly in pediatric and booster vaccination schedules.
  • In the disease segment, tetanus remained the dominant contributor to market growth in 2024. The high incidence of tetanus-related complications, particularly in unvaccinated populations and high-risk groups such as newborns and trauma patients, has driven demand for effective vaccination strategies, reinforcing the importance of tetanus toxoid immunization.
  • In end-use segment, hospitals dominated the market in 2024. Hospitals play a crucial role in vaccination programs, emergency prophylaxis, and post-exposure tetanus management, ensuring timely administration of vaccines, especially in cases of injuries and wound care. The availability of trained healthcare professionals further supports the efficiency of hospital-based immunization.
  • North America led the market in 2024, driven by advanced healthcare infrastructure, well-established immunization programs, and increasing awareness about vaccine-preventable diseases. Favorable government policies and initiatives promoting routine and booster vaccinations have further contributed to regional market dominance.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Tetanus Toxoid Vaccine Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Increasing government immunization programs
      • 3.3.1.2. Rising awareness & preventive healthcare
      • 3.3.1.3. Increasing birth rates & pediatric vaccination
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Vaccine shortages & supply chain issues
      • 3.3.2.2. Low awareness in developing regions
  • 3.4. Tetanus Toxoid Vaccine Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Tetanus Toxoid Vaccine Market: By Vaccine Estimates & Trend Analysis

  • 4.1. Tetanus Toxoid Vaccine Market: Vaccine Segment Dashboard
  • 4.2. Tetanus Toxoid Vaccine Market: By Vaccine Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Diphtheria, Tetanus, and Pertussis (DTaP)
    • 4.3.1. Diphtheria, Tetanus, and Pertussis (DTaP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Diphtheria and Tetanus (DT)
    • 4.4.1. Diphtheria and Tetanus (DT) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Tetanus, Diphtheria and Pertussis (Tdap)
    • 4.5.1. Tetanus, Diphtheria and Pertussis (Tdap) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Tetanus Toxoid Vaccine Market: Disease Estimates & Trend Analysis

  • 5.1. Tetanus Toxoid Vaccine Market: Disease Segment Dashboard
  • 5.2. Tetanus Toxoid Vaccine Market: By Disease Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Tetanus
    • 5.3.1. Tetanus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Diphtheria
    • 5.4.1. Diphtheria Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Tetanus Toxoid Vaccine Market: End Use Estimates & Trend Analysis

  • 6.1. Tetanus Toxoid Vaccine Market: End Use Segment Dashboard
  • 6.2. Tetanus Toxoid Vaccine Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Specialty Clinics
    • 6.4.1. Specialty Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Tetanus Toxoid Vaccine Market: Regional Estimates & Trend Analysis

  • 7.1. Tetanus Toxoid Vaccine Market Share, By Region, 2024 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018- 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Norway
      • 7.3.8.1. Norway Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Sweden
      • 7.3.9.1. Sweden Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. Kuwait
      • 7.6.4.1. Kuwait Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. South Africa Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Pfizer, Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. GSK plc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Sanofi
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Merck & Co., Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Grifols, S.A.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Emergent BioSolutions Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Virbac
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Zoetis Services LLC
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Ceva.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Abbott
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives

List of Tables:

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 4 Global Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 5 Global Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 6 North America Tetanus Toxoid Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 8 North America Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 9 North America Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 10 U.S. Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 11 U.S. Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 12 U.S. Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Canada Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 14 Canada Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 15 Canada Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 16 Mexico Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 17 Mexico Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 18 Mexico Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 19 Europe Tetanus Toxoid Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 21 Europe Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 22 Europe Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 23 Germany Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 24 Germany Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 25 Germany Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 U.K. Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 27 U.K. Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 28 U.K. Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 29 France Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 30 France Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 31 France Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Italy Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 33 Italy Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 34 Italy Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Spain Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 36 Spain Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 37 Spain Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 38 Denmark Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 39 Denmark Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 40 Denmark Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Sweden Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 42 Sweden Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 43 Sweden Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 44 Norway Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 45 Norway Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 46 Norway Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Tetanus Toxoid Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 China Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 52 China Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 53 China Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Japan Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 55 Japan Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 56 Japan Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 57 India Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 58 India Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 59 India Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 60 South Korea Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 61 South Korea Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 62 South Korea Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 Australia Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 64 Australia Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 65 Australia Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 66 Thailand Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 67 Thailand Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 68 Thailand Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 69 Latin America Tetanus Toxoid Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 71 Latin America Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 72 Latin America Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 73 Brazil Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 74 Brazil Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 75 Brazil Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 76 Argentina Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 77 Argentina Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 78 Argentina Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Tetanus Toxoid Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 83 South Africa Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 84 South Africa Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 85 South Africa Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 89 UAE Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 90 UAE Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 91 UAE Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Tetanus toxoid vaccine market segmentation
  • Fig. 8 Market snapshot, 2024
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 Market challenge relevance analysis (current & future impact)
  • Fig. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Tetanus toxoid vaccine market: Vaccine movement analysis
  • Fig. 16 Tetanus toxoid vaccine market: Vaccine outlook and key takeaways
  • Fig. 17 Diphtheria, tetanus, and pertussis (DTaP) tetanus toxoid vaccine market estimates and forecasts, 2018 - 2030
  • Fig. 18 Diphtheria and tetanus (DT) tetanus toxoid vaccine market estimates and forecasts, 2018 - 2030
  • Fig. 19 Tetanus, diphtheria and pertussis (Tdap) tetanus toxoid vaccine market estimates and forecasts, 2018 - 2030
  • Fig. 20 Tetanus, Diphtheria and Pertussis (Tdap) tetanus toxoid vaccine market estimates and forecasts, 2018 - 2030
  • Fig. 21 Tetanus toxoid vaccine market: Disease movement analysis
  • Fig. 22 Tetanus toxoid vaccine market: Disease outlook and key takeaways
  • Fig. 23 Tetanus market estimates and forecasts, 2018 - 2030
  • Fig. 24 Diphtheria market estimates and forecasts, 2018 - 2030
  • Fig. 25 Others market estimates and forecasts, 2018 - 2030
  • Fig. 26 Tetanus toxoid vaccine market: End use movement analysis
  • Fig. 27 Tetanus toxoid vaccine market: End use outlook and key takeaways
  • Fig. 28 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 29 Specialty clinics market estimates and forecasts, 2018 - 2030
  • Fig. 30 Others market estimates and forecasts, 2018 - 2030
  • Fig. 31 Regional Marketplace: Key Takeaways
  • Fig. 32 Regional Outlook, 2024 & 2030
  • Fig. 33 Global tetanus toxoid vaccine market, Region Movement Analysis
  • Fig. 34 North America tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 36 Canada tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 40 U.K. tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 41 France tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 44 Denmark tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 49 China tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 50 India tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 51 Australia tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 58 South Africa tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 59 Saudi Arabia tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 60 UAE tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait tetanus toxoid vaccine market, 2018 - 2030 (USD Million)